摘要
目的观察美托洛尔联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭的安全性和效果。方法选取我院2015年4月至2017年1月收治的65例老年重症心力衰竭患者,按治疗方式不同分为两组。对照组(30例)采用常规内科治疗,观察组(35例)在此基础上采用美托洛尔联合厄贝沙坦氢氯噻嗪治疗。比较两组患者的治疗效果、心功能水平、症状恢复时间以及不良反应。结果观察组的总有效率为94.29%,明显高于对照组的76.67%(P<0.05)。治疗后,观察组的心功能水平(LVEF、BNP、心功能分级)明显优于对照组(P<0.05)。观察组的心功能、心电图恢复正常时间以及住院时间均短于对照组(P<0.05)。两组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论美托洛尔联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭具有较好的疗效,明显改善患者的心功能,不良反应少,恢复快,值得临床推广应用。
Objective To observe the safety and effect of metoprolol combined with irbesartan and hydrochlorothiazide in the treatment of elderly patients with severe heart failure. Methods 65 cases of patients with severe heart failure admitted to our hospital from April 2015 to January 2017 were selected and divided into two groups according to different treatments. The control group （30 cases） received conventional internal medicine, while the observation group （35 cases） received metoprolol combined with irbesartan and hydrochlorothiazide on this basis. The treatment effect, heart function level, symptom recovery time and adverse reactions were compared between two groups. Results The total effective rate of observation group was 94.29%, significantly higher than 76.67% of control group （P 〈0.05）. After treatment, the heart function level （LVEF, BNP and heart function grading） of observation group was significantly better than that of control group （P 〈0.05）. The time of cardiac function and ECG returning to normal and hospitalization time of observation group were shorter than those of control group （P 〈0.05）. No statistical difference was found in the incidence of adverse reactions between two groups （P 〉0.05）. Conclusions Metoprolol combined with irbesartan and hydrochlorothiazide has better curative effect in the treatment of elderly patients with severe heart failure and significantly improves patients＇ heart function with fewer adverse reactions and rapid recovery, which is worthy of clinical promotion and application.
出处
《临床医学工程》
2017年第11期1591-1592,共2页
Clinical Medicine & Engineering
关键词
重症心力衰竭
美托洛尔
厄贝沙坦氢氯噻嗪
Severe heart failure
Metoprolol
Irbesartan and hydrochlorothiazide
